|
Valero-Lopez G, Millan-Pascual J, Iniesta-Martinez F, Delgado-Marin JL, Jimenez-Veiga J, Tejero-Martin AB, Leon-Hernandez A, Zamarro-Parra J, Morales-Ortiz A, Meca-Lallana JE. Treatment with natalizumab during pregnancy in multiple sclerosis: The experience of implementing a clinical practice protocol (NAP-30). Mult Scler Relat Disord. 2022 Oct;66:104038. doi: 10.1016/j.msard.2022.104038. Epub 2022 Jul 7. PubMed PMID: 35870370.
AÑO: 2022; IF: 4.0
|
35870370
|
Meca-Lallana JE, Casanova B, Rodriguez-Antiguedad A, Eichau S, Izquierdo G, Duran C, Rio J, Hernandez MA, Calles C, Prieto-Gonzalez JM, Ara JR, Uria DF, Costa-Frossard L, Garcia-Merino A, Oreja-Guevara C. Consensus on early detection of disease progression in patients with multiple sclerosis. Front Neurol. 2022 Jul 28;13:931014. doi: 10.3389/fneur.2022.931014. eCollection 2022. PubMed PMID: 35968319; PubMed Central PMCID: PMC9366521.
AÑO: 2022; IF: 3.4
|
|
Meca-Lallana JE, Fernandez-Prada M, Garcia Vazquez E, Moreno Guillen S, Otero Romero S, Rus Hidalgo M, Villar Guimerans LM, Eichau Madueno S, Fernandez Fernandez O, Izquierdo Ayuso G, Alvarez Cermeno JC, Arnal Garcia C, Arroyo Gonzalez R, Brieva Ruiz L, Calles Hernandez C, Garcia Merino A, Gonzalez Platas M, Hernandez Perez MA, Moral Torres E, Olascoaga Urtaza J, Oliva-Nacarino P, Oreja-Guevara C, Ortiz Castillo R, Oterino A, Prieto Gonzalez JM, Ramio-Torrenta L, Rodriguez-Antiguedad A, Saiz A, Tintore M, Montalban Gairin X. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain. Neurologia (Engl Ed). 2020 Jan 25;37(8):615-630. doi: 10.1016/j.nrl.2019.11.003. Print 2022 Oct. English, Spanish. PubMed PMID: 31987648.
AÑO: 2022; IF: 3.109
|
|
Fernandez-Velasco JI, Monreal E, Kuhle J, Meca-Lallana V, Meca-Lallana J, Izquierdo G, Oreja-Guevara C, Gascon-Gimenez F, Sainz de la Maza S, Walo-Delgado PE, Lapuente-Suanzes P, Maceski A, Rodriguez-Martin E, Roldan E, Villarrubia N, Saiz A, Blanco Y, Diaz-Perez C, Valero-Lopez G, Diaz-Diaz J, Aladro Y, Brieva L, Iniguez C, Gonzalez-Suarez I, Rodriguez de Antonio LA, Garcia-Dominguez JM, Sabin J, Llufriu S, Masjuan J, Costa-Frossard L, Villar LM. Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology. Front Immunol. 2022 Mar 21;13:842354. doi: 10.3389/fimmu.2022.842354. eCollection 2022. PubMed PMID: 35386690; PubMed Central PMCID: PMC8977599.
AÑO: 2022; IF: 7.3
|
|
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. PubMed PMID: 35483387.
AÑO: 2022; IF: 48.0
|